4913843 said its normalized net income for the fiscal third quarter ended Feb. 28 came to ¥132.80 per share, a decline from ¥136.78 per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥2.63 billion, a decrease from ¥2.71 billion in the prior-year period.
The normalized profit margin fell to 2.6% from 3.0% in the year-earlier period.
Total revenue grew 11.1% on an annual basis to ¥101.71 billion from ¥91.55 billion, and total operating expenses grew 12.1% year over year to ¥98.23 billion from ¥87.60 billion.
eported net income increased 15.9% from the COSMOS Pharmaceutical Corp.
